Subscribe To
MEDS / All You Need to Know About TRxADE (MEDS) Rating Upgrade to Strong Buy
MEDS News
By Accesswire
July 31, 2023
TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.
TAMPA, FL / ACCESSWIRE / July 31, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy more_horizontal
By InvestorPlace
June 27, 2023
Why Is Trxade Health (MEDS) Stock Down 13% Today?
Trxade Health (NASDAQ: MEDS ) stock is falling on Tuesday after the company announced it would undergo a merger with Superlatus . That merger will see more_horizontal
By InvestorPlace
June 22, 2023
TRxADE Health (MEDS) Stock Soars 60% on Reverse Split
One of the biggest movers in today's market is little-known health tech company TRxADE Health (NASDAQ: MEDS ). Shares of MEDS stock have rocketed more more_horizontal
By Seeking Alpha
May 15, 2023
TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript
TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q1 2023 Earnings Conference Call May 15, 2023 6:00 PM ET Company Participants Prashant Patel - Interim Chief Financ more_horizontal
By Zacks Investment Research
May 15, 2023
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
TRxADE (MEDS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.12 more_horizontal
By Accesswire
April 25, 2023
TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.
TAMPA, FL / ACCESSWIRE / April 25, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmac more_horizontal
By Seeking Alpha
March 27, 2023
TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript
TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q4 2022 Earnings Conference Call March 27, 2023 5:30 PM ET Company Participants Prashant Patel - CFO Surendra Ajjar more_horizontal
By Zacks Investment Research
March 27, 2023
TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates
TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold cl more_horizontal